Use of PET for monitoring cancer therapy and for predicting outcome.
暂无分享,去创建一个
[1] G. van Kaick,et al. Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] L. Specht,et al. FDG-PET in the clinical management of Hodgkin lymphoma. , 2004, Critical reviews in oncology/hematology.
[3] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[4] Elisabeth Kjellén,et al. FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma , 2002, Head and Neck.
[5] S C Huang,et al. Anatomy of SUV. Standardized uptake value. , 2000, Nuclear medicine and biology.
[6] J. Thie. Understanding the standardized uptake value, its methods, and implications for usage. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] M. Schwaiger,et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Gerald Antoch,et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] A. Alavi,et al. Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.
[10] H. Schäfers,et al. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. , 2004, The Journal of thoracic and cardiovascular surgery.
[11] M. Thomas,et al. Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. , 2001, Chest.
[12] J. Keyes. SUV: standard uptake or silly useless value? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] M. Schwaiger,et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Rota Kops,et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[16] G. Glatting,et al. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] R L Wahl,et al. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] L M Hamberg,et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] J. Hanley,et al. The effect of measuring error on the results of therapeutic trials in advanced cancer , 1976, Cancer.
[20] B. Siegel,et al. Neoplasms of the esophagus and stomach. , 2004, Seminars in nuclear medicine.
[21] P F Sharp,et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R L Wahl,et al. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. , 1993, Radiology.
[23] T. Reichert,et al. Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. , 2003, Oral oncology.
[24] Imran Zoberi,et al. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] David Binns,et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. , 2004, International journal of radiation oncology, biology, physics.
[27] T Ido,et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] R. Wahl,et al. Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] Danny Rischin,et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Podoloff,et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] Wolfgang A Weber,et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Chariklia D. Giannopoulou. The role of SPET and PET in monitoring tumour response to therapy , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[33] J. Leonard,et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] J Nuyts,et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.
[35] J. Vansteenkiste,et al. Positron emission tomography in the management of non-small cell lung cancer. , 2004, Hematology/oncology clinics of North America.
[36] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[37] J. Nährig,et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] P. Dupont,et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. , 2003, Blood.
[39] T. Golub,et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.
[40] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[41] U. Cremerius,et al. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma , 2001, Nuklearmedizin.
[42] A. D. Van den Abbeele,et al. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). , 2002, European journal of cancer.
[43] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[44] Marvin Bergsneider,et al. Measurement of the global lumped constant for 2-deoxy-2-[18F]fluoro-D-glucose in normal human brain using [15O]water and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography imaging. A method with validation based on multiple methodologies. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[45] Z. Keidar,et al. Positron emission tomography in the evaluation of lymphoma. , 2004, Seminars in nuclear medicine.
[46] J. Petiot,et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.
[47] L. Mortelmans,et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] L. Kostakoglu,et al. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[49] V. Diehl,et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. , 2001, Blood.
[50] Adriaan A. Lammertsma,et al. Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[51] Mark Muzi,et al. Positron emission tomography imaging of brain tumors. , 2003, Neuroimaging clinics of North America.
[52] Wolfgang A Weber,et al. Monitoring response to treatment in patients utilizing PET. , 2005, Radiologic clinics of North America.
[53] O. Schober,et al. Assessment of therapy response by FDG PET in pediatric patients. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[54] J. Ajani,et al. 2‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma , 2004, Cancer.
[55] C. Sawyers. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. , 2003, Genes & development.
[56] M. Schwaiger,et al. Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[57] P. Dupont,et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] 山根 登茂彦. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas , 2005 .
[59] M. Christian,et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. , 1999, Journal of the National Cancer Institute.
[60] N. Gupta,et al. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. , 1996, Nuclear medicine communications.
[61] R. Hustinx,et al. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[62] C S Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[63] R L Wahl,et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. , 1995, Radiology.
[64] R. Boellaard,et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[65] Lilli Geworski,et al. Recovery correction for quantitation in emission tomography: a feasibility study , 2000, European Journal of Nuclear Medicine.
[66] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[67] S. Reske. PET and restaging of malignant lymphoma including residual masses and relapse , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[68] M. Welch,et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] M. Phelps,et al. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[70] H. Höfler,et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.
[71] D R Alessi,et al. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? , 2001, Journal of cell science.
[72] D. Podoloff,et al. The Role of 18 F-FDG PET in Staging and Early Prediction of Response to Therapy of Recurrent Gastrointestinal Stromal Tumors , 2003 .
[73] G. Delling,et al. Morphological grades of regression in osteosarcoma after polychemotherapy — Study COSS 80 , 2004, Journal of Cancer Research and Clinical Oncology.
[74] M. Schwaiger,et al. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[75] Y Yonekura,et al. Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: a PET study. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[76] W. Weber,et al. Imaging of esophageal and gastric cancer. , 2004, Seminars in oncology.
[77] Winfried Brenner,et al. PET imaging of osteosarcoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[78] A. Alavi,et al. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[79] Sung-Cheng Huang,et al. Anatomy of SUV , 2000 .
[80] M Schwaiger,et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[81] Lale Kostakoglu,et al. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[82] P. Baas,et al. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[83] M. Schwaiger,et al. Correlation Between Postoperative 3-[123I]Iodo-l-α-Methyltyrosine Uptake and Survival in Patients with Gliomas , 2001 .
[84] V. Diehl,et al. Prognostic Significance of 18 F-fluorodeoxyglucose Positron Emission Tomography in Lymphoma , 2003, Leukemia & lymphoma.
[85] L. Mortelmans,et al. Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[86] M. Schwaiger,et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] T. Miller,et al. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[88] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[89] J. Dobkin,et al. Glucose uptake by gliomas after treatment. A positron emission tomographic study. , 1989, Archives of neurology.
[90] J. Nährig,et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] Yuji Nakamoto,et al. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[92] W. Winkelmann,et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] M. Birnbaum,et al. Role of Akt/protein kinase B in metabolism , 2002, Trends in Endocrinology & Metabolism.